Phase
Condition
Pancreatitis
Adenocarcinoma
Digestive System Neoplasms
Treatment
all approved chemotherapeutic agents from second line
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
18 years, female and male
ECOG (Eastern Cooperative Oncology Group) Scale 0-2
Diagnosis of histologically confirmed locally advanced inoperable and/or metastaticPDAC
Patients undergoing palliative 1st line therapy with a platinum- or gemcitabine-based chemotherapy in case of previous (neo)adjuvant therapy also patients whoreceive nal-Irinotecan/5-FU/Leukovorin as palliative first line are eglible
Signed informed consent for prospective patients, for retrospective cases noinformed consent is required
Exclusion
Exclusion Criteria:
Patients with locally advanced operable PDAC who do not receive palliativechemotherapy
Patients with locally advanced borderline resectable PDAC who do not receivepalliative chemotherapy
Study Design
Study Description
Connect with a study center
Medical University Graz Department of Oncology
Graz, Styria 8036
AustriaActive - Recruiting
Ordensklinikum Linz
Linz, Upper Austria 4010
AustriaActive - Recruiting
Krankenhaus der Barmherzigen Brüder
Graz, 8020
AustriaActive - Recruiting
Universitätsklinikum Innsbruck,
Innsbruck, 6020
AustriaActive - Recruiting
Landesklinikum Klagenfurt
Klagenfurt, 9020
AustriaActive - Recruiting
Universitätsklinikum St. Pölten
St. Pölten, 3100
AustriaActive - Recruiting
Pancreatic Cancer Unit des Comprehensive Cancer Center (CCC-PCU)
Wien, 1090
AustriaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.